• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医师拒绝将患者纳入一项重症监护试验:以血栓预防为例的一项病例研究。

Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.

出版信息

Intensive Care Med. 2013 Dec;39(12):2115-25. doi: 10.1007/s00134-013-3074-x.

DOI:10.1007/s00134-013-3074-x
PMID:24022796
Abstract

PURPOSE

To analyze the frequency, rationale and determinants of attending physicians requesting that their eligible patients not be approached for participation in a thromboprophylaxis trial.

METHODS

Research personnel in 67 centers prospectively documented eligible non-randomized patients due to physicians declining to allow their patients to be approached.

RESULTS

In 67 centers, 3,764 patients were enrolled, but 1,460 eligible patients had no consent encounter. For 218 (14.9 %) of these, attending physicians requested that their patients not be approached. The most common reasons included a high risk of bleeding (31.2 %) related to fear of heparin bioaccumulation in renal failure, the presence of an epidural catheter, peri-operative status or other factors; specific preferences for thromboprophylaxis (12.4 %); morbid obesity (9.6 %); uncertain prognosis (6.4 %); general discomfort with research (3.7 %) and unclear reasons (17.0 %). Physicians were more likely to decline when approached by less experienced research personnel; considering those with[10 years of experience as the reference category, the odds ratios (OR) for physician refusals to personnel without trial experience was 10.47 [95 % confidence interval (CI) 2.19-50.02] and those with less than 10 years experience was 1.72 (95 % CI 0.61-4.84). Physicians in open rather than closed units were more likely to decline (OR 4.26; 95 % CI 1.27-14.34). Refusals decreased each year of enrollment compared to the pilot phase.

CONCLUSIONS

Tracking, analyzing, interpreting and reporting the rates and reasons for physicians declining to allow their patients to be approached for enrollment provides insights into clinicians' concerns and attitudes to trials. This information can encourage physician communication and education, and potentially enhance efficient recruitment.

摘要

目的

分析主治医生要求其符合条件的患者不参与血栓预防试验的频率、理由和决定因素。

方法

67 个中心的研究人员前瞻性地记录了因医生拒绝允许患者参与而不符合随机分组条件的合格患者。

结果

在 67 个中心,共纳入 3764 名患者,但 1460 名符合条件的患者未进行同意访谈。对于其中 218 名(14.9%)患者,主治医生要求不接触他们的患者。最常见的原因包括因担心肝素在肾衰竭中的生物蓄积而导致出血风险高(31.2%),存在硬膜外导管、围手术期状态或其他因素;对血栓预防的特殊偏好(12.4%);病态肥胖(9.6%);预后不确定(6.4%);对研究的一般不适(3.7%)和原因不明(17.0%)。当研究人员经验不足时,医生更有可能拒绝;与[10 年经验的医生相比,无试验经验的医生拒绝率的比值比(OR)为 10.47(95%置信区间(CI)为 2.19-50.02),经验不足 10 年的医生为 1.72(95%CI 为 0.61-4.84)。与封闭式病房相比,开放式病房的医生更有可能拒绝(OR 4.26;95%CI 1.27-14.34)。与试点阶段相比,每年的入组人数都有所减少。

结论

跟踪、分析、解释和报告医生拒绝允许其患者参与招募的比例和原因,可深入了解临床医生对试验的关注和态度。这些信息可以鼓励医生之间的沟通和教育,并有可能提高招募效率。

相似文献

1
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.医师拒绝将患者纳入一项重症监护试验:以血栓预防为例的一项病例研究。
Intensive Care Med. 2013 Dec;39(12):2115-25. doi: 10.1007/s00134-013-3074-x.
2
Physicians declining patient enrollment in clinical trials: what are the implications?医生拒绝患者参与临床试验:这意味着什么?
Intensive Care Med. 2014 Jan;40(1):117-9. doi: 10.1007/s00134-013-3151-1. Epub 2013 Nov 20.
3
Rates and determinants of informed consent: a case study of an international thromboprophylaxis trial.知情同意率及其决定因素:一项国际血栓预防试验的案例研究。
J Crit Care. 2013 Feb;28(1):28-39. doi: 10.1016/j.jcrc.2012.08.005. Epub 2012 Oct 22.
4
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.重症监护预防血栓栓塞试验方案和分析计划。
J Crit Care. 2011 Apr;26(2):223.e1-9. doi: 10.1016/j.jcrc.2011.02.010.
5
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.危重症患者肝素预防血栓栓塞事件治疗中主要出血的风险因素和影响。
Intensive Care Med. 2013 Dec;39(12):2135-43. doi: 10.1007/s00134-013-3044-3. Epub 2013 Aug 14.
6
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.达肝素对合并肾功能不全的重症内科及外科患者的血栓预防作用
J Crit Care. 2005 Dec;20(4):357-63. doi: 10.1016/j.jcrc.2005.09.009.
7
Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.重症监护中血栓栓塞预防的经济学评估试验(E-PROTECT):一项随机对照试验的研究方案
Trials. 2014 Dec 20;15:502. doi: 10.1186/1745-6215-15-502.
8
Characteristics Associated With Consent and Reasons for Declining in a Randomized Trial in Pregnancy.与妊娠随机试验中同意和拒绝相关的特征。
Obstet Gynecol. 2020 Oct;136(4):731-737. doi: 10.1097/AOG.0000000000003998.
9
Research recruitment practices and critically ill patients. A multicenter, cross-sectional study (the Consent Study).研究招募实践与重症患者。一项多中心、横断面研究(同意研究)。
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1212-8. doi: 10.1164/rccm.201208-1537OC.
10
Obtaining surrogate consent for a minimal-risk research study in the intensive care unit setting.在重症监护病房环境中,为一项低风险研究获得替代同意。
Clin Trials. 2013 Feb;10(1):93-6. doi: 10.1177/1740774512464727. Epub 2012 Nov 20.

引用本文的文献

1
An evaluation of factors that may influence clinicians' decisions not to enroll eligible patients into randomized trials in critical care.评估可能影响临床医生决定不将符合条件的患者纳入重症监护随机试验的因素。
PLoS One. 2021 Jul 27;16(7):e0255361. doi: 10.1371/journal.pone.0255361. eCollection 2021.
2
Detailed systematic analysis of recruitment strategies in randomised controlled trials in patients with an unscheduled admission to hospital.对非计划入院患者的随机对照试验中的招募策略进行详细的系统分析。
BMJ Open. 2018 Feb 2;8(2):e018581. doi: 10.1136/bmjopen-2017-018581.
3
biotics: Prevention of evere neumonia and ndotracheal olonization rial-PROSPECT: protocol for a feasibility randomized pilot trial.

本文引用的文献

1
High-frequency oscillation in early acute respiratory distress syndrome.早期急性呼吸窘迫综合征中的高频振荡。
N Engl J Med. 2013 Feb 28;368(9):795-805. doi: 10.1056/NEJMoa1215554. Epub 2013 Jan 22.
2
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.重症监护预防血栓栓塞试验方案和分析计划。
J Crit Care. 2011 Apr;26(2):223.e1-9. doi: 10.1016/j.jcrc.2011.02.010.
3
Dalteparin versus unfractionated heparin in critically ill patients.达肝素与普通肝素在危重症患者中的比较。
生物制剂:预防重症肺炎和气管内定植——细菌-PROSPECT:一项可行性随机试点试验的方案。 (注:原文中“evere neumonia”应是“severe pneumonia”;“ndotracheal olonization”应是“endotracheal colonization” ,译文已按正确内容翻译)
Pilot Feasibility Stud. 2015 May 24;1:19. doi: 10.1186/s40814-015-0013-3. eCollection 2015.
4
Early goal-directed therapy: do we have a definitive answer?早期目标导向治疗:我们有明确的答案了吗?
Intensive Care Med. 2016 Jun;42(6):1048-50. doi: 10.1007/s00134-016-4295-6. Epub 2016 Mar 7.
5
Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.标准和加速起始肾脏替代治疗在急性肾损伤中的比较。
Kidney Int. 2015 Oct;88(4):897-904. doi: 10.1038/ki.2015.184. Epub 2015 Jul 8.
6
PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain.PROF-ETEV 研究:西班牙重症监护病房静脉血栓栓塞症的预防。
Intensive Care Med. 2014 Nov;40(11):1698-708. doi: 10.1007/s00134-014-3442-1. Epub 2014 Aug 20.
7
Year in review in Intensive Care Medicine 2013: II. Sedation, invasive and noninvasive ventilation, airways, ARDS, ECMO, family satisfaction, end-of-life care, organ donation, informed consent, safety, hematological issues in critically ill patients.《2013年重症医学年度回顾:II. 镇静、有创及无创通气、气道、急性呼吸窘迫综合征、体外膜肺氧合、家属满意度、临终关怀、器官捐献、知情同意、安全、危重症患者的血液学问题》
Intensive Care Med. 2014 Mar;40(3):305-19. doi: 10.1007/s00134-014-3217-8. Epub 2014 Jan 24.
8
Physicians declining patient enrollment in clinical trials: what are the implications?医生拒绝患者参与临床试验:这意味着什么?
Intensive Care Med. 2014 Jan;40(1):117-9. doi: 10.1007/s00134-013-3151-1. Epub 2013 Nov 20.
N Engl J Med. 2011 Apr 7;364(14):1305-14. doi: 10.1056/NEJMoa1014475. Epub 2011 Mar 22.
4
Comparison of dopamine and norepinephrine in the treatment of shock.多巴胺与去甲肾上腺素治疗休克的比较。
N Engl J Med. 2010 Mar 4;362(9):779-89. doi: 10.1056/NEJMoa0907118.
5
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.实用-解释性连续统指标总结(PRECIS):一种帮助试验设计者的工具。
CMAJ. 2009 May 12;180(10):E47-57. doi: 10.1503/cmaj.090523. Epub 2009 Apr 16.
6
Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial.“正常与强化水平随机评估(RENAL)替代疗法试验”中的筛查与研究入组情况
Blood Purif. 2009;27(2):199-205. doi: 10.1159/000195091.
7
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.达肝素低分子量肝素对重症肾功能严重不全患者深静脉血栓形成的预防:安全性和药效学评估:DIRECT研究
Arch Intern Med. 2008 Sep 8;168(16):1805-12. doi: 10.1001/archinte.168.16.1805.
8
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.接受达肝素血栓预防的严重肾功能不全重症患者的静脉血栓栓塞和出血:患病率、发病率及危险因素
Crit Care. 2008;12(2):R32. doi: 10.1186/cc6810. Epub 2008 Mar 3.
9
Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.去甲肾上腺素加多巴酚丁胺与单独使用肾上腺素治疗感染性休克的对比:一项随机试验。
Lancet. 2007 Aug 25;370(9588):676-84. doi: 10.1016/S0140-6736(07)61344-0.
10
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.重症监护中血栓栓塞的预防(PROTECT)试验:一项试点研究。
J Crit Care. 2005 Dec;20(4):364-72. doi: 10.1016/j.jcrc.2005.09.010.